Evolus (NASDAQ:EOLS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $27.00 price target on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2024 earnings at $0.01 EPS, FY2026 earnings at $0.40 EPS, FY2027 earnings at $1.31 EPS and FY2028 earnings at $2.18 EPS.

Other research analysts also recently issued research reports about the company. Barclays increased their price target on Evolus from $16.00 to $20.00 and gave the company an overweight rating in a research note on Friday, September 13th. Needham & Company LLC restated a buy rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Price Performance

Shares of EOLS stock opened at $16.34 on Thursday. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -15.56 and a beta of 1.31. Evolus has a 12 month low of $7.44 and a 12 month high of $17.70. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26. The stock has a 50-day moving average price of $15.13 and a 200 day moving average price of $13.27.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. Research analysts expect that Evolus will post -0.64 EPS for the current year.

Insider Transactions at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Evolus

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC bought a new position in shares of Evolus during the 2nd quarter worth approximately $43,000. Quarry LP acquired a new stake in Evolus in the 2nd quarter valued at $54,000. Sierra Summit Advisors LLC bought a new stake in Evolus during the 4th quarter worth about $119,000. Profund Advisors LLC acquired a new position in shares of Evolus during the 2nd quarter worth about $130,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Evolus by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock valued at $154,000 after acquiring an additional 4,355 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.